On July 26, 2023, the Prostate Health Education Network (PHEN) partnered with the Memorial Sloan Kettering Cancer Center (MSKCC) for an informative Clinical Trials Learning Session. The session was spearheaded by PHEN’s Director of Clinical Trials and Patient Education Dr. Keith Crawford. It featured MSKCC’s Genitourinary Oncologist Dr. Andrew Laccetti as the main speaker.
In his opening remarks, Dr. Crawford emphasized the importance of increasing participation by African American men in clinical trials. He pinpointed a crucial issue: most clinical trials primarily focus on European ancestry, potentially overlooking unique genetic factors in Black men that could impact prostate cancer treatments.
Highlighted Topics:
- ADream: a clinical trial is being conducted to determine if men with metastatic hormone sensitive prostate cancer (mHSPC) receiving intermittent ADT have fewer adverse events and poor quality of life (QOL) associated with continuous ADT.
- AMG509: a clinical trial that investigates how well patients with metastatic castration-resistant prostate cancer (mCRPC) respond to a targeted prostate cancer immunotherapy.
- PROMISE Registry: a prostate cancer registry conducted in the US, which offers 5,000 prostate cancer patients free at-home genetic testing.
The session garnered the attention of around 30 attendees. At its conclusion, an interactive poll was conducted to gauge participant feedback.
- Overall Satisfaction: An impressive 91% of the participants were “very satisfied” with the information and presentation.
- Content Quality: 82% believed that the content thoroughly met their expectations.
- Presentation Rating: 73% rated the presentation’s quality as “excellent,” with the remaining 27% deeming it “good.”
- Presenter’s Evaluation: A significant 82% of the attendees found the presenters to be “excellent.”
Furthermore, the attendees had a more robust grasp of immuno-oncology and its role in targeting prostate cancer cells.
For those who missed the live session or wish to revisit it, a recorded version is accessible on PHENTV.com. The detailed results of the post-session poll can also be found here.